PCVX
Vaxcyte Inc.
Company Overview
| Mkt Cap | $5.48B | Price | $47.78 |
| Volume | 1.79M | Change | +0.23% |
| P/E Ratio | -11.8 | Open | $47.55 |
| Revenue | -- | Prev Close | $47.67 |
| Net Income | $-463.9M | 52W Range | $27.66 - $94.76 |
| Div Yield | N/A | Target | $98.00 |
| Overall | 63 | Value | 60 |
| Quality | -- | Technical | 66 |
No chart data available
About Vaxcyte Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Latest News
Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)
Needham Sticks to Its Buy Rating for Vaxcyte (PCVX)
Vaxcyte, Inc. Reports Q3 2025 Financial Results
Vaxcyte’s VAX-31 Study: A Potential Game-Changer in Infant Vaccination
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PCVX | $47.78 | +0.2% | 1.79M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |